A pilot cost-effectiveness analysis of treatments in newly diagnosed high-grade gliomas: the example of 5-aminolevulinic Acid compared with white-light surgery

Susana Esteves, Marta Alves, Marta Castel-Branco, Walter Stummer, Susana Esteves, Marta Alves, Marta Castel-Branco, Walter Stummer

Abstract

Background: High-grade gliomas are aggressive, incurable tumors characterized by extensive diffuse invasion of the normal brain parenchyma. Novel therapies at best prolong survival; their costs are formidable and benefit is marginal. Economic restrictions thus require knowledge of the cost-effectiveness of treatments. Here, we show the cost-effectiveness of enhanced resections in malignant glioma surgery using a well-characterized tool for intraoperative tumor visualization, 5-aminolevulinic acid (5-ALA).

Objective: To evaluate the cost-effectiveness of 5-ALA fluorescence-guided neurosurgery compared with white-light surgery in adult patients with newly diagnosed high-grade glioma, adopting the perspective of the Portuguese National Health Service.

Methods: We used a Markov model (cohort simulation). Transition probabilities were estimated with the use of data from 1 randomized clinical trial and 1 noninterventional prospective study. Utility values and resource use were obtained from published literature and expert opinion. Unit costs were taken from official Portuguese reimbursement lists (2012 values). The health outcomes considered were quality-adjusted life-years, life-years, and progression-free life-years. Extensive 1-way and probabilistic sensitivity analyses were performed.

Results: The incremental cost-effectiveness ratios are below &OV0556;10 000 in all evaluated outcomes, being around &OV0556;9100 per quality-adjusted life-year gained, &OV0556;6700 per life-year gained, and &OV0556;8800 per progression-free life-year gained. The probability of 5-ALA fluorescence-guided surgery cost-effectiveness at a threshold of &OV0556;20000 is 96.0% for quality-adjusted life-year, 99.6% for life-year, and 98.8% for progression-free life-year.

Conclusion: 5-ALA fluorescence-guided surgery appears to be cost-effective in newly diagnosed high-grade gliomas compared with white-light surgery. This example demonstrates cost-effectiveness analyses for malignant glioma surgery to be feasible on the basis of existing data.

Figures

FIGURE 1
FIGURE 1
Influence diagram. 5-ALA, 5-aminolevulinic acid; PDeathCR, probability of death for patients with complete resection (time dependent); PDeathPR, probability of death in patients with partial resection (time dependent); Surg2CR_5ALA, probability of complete resection with 5-ALA surgery; StaCR2Pro, probability of progression in patients with complete resection; Surg2CRstand, probability of complete resection with white-light surgery; StaPR2Pro, probability of progression in patients with partial resection; Surg2D, probability of death within 4 weeks of initial debulking surgery; Surg2PR_5ALA, probability of partial resection with 5-ALA surgery; Surg2PRstand, probability of partial resection with white-light surgery.
FIGURE 2
FIGURE 2
Tornado diagrams of 1-way sensitivity analyses concerning incremental cost-effectiveness ratios, National Health Service perspective. A, incremental cost per quality-adjusted life-year gained (in euros). B, incremental cost per life-year gained (in euros). C, incremental cost per progression-free life-year gained (in euros). PDeathCR, probability of death for patients with complete resection; PDeathPR, probability of death in patients with partial resection; Progressive >W52, progressive disease state after week 52; ProgressiveW1, first week in progressive disease state; ProgressiveW2-W52, progressive disease state from week 2 to 52; StableNoTherapy, stable disease after partial or complete resection without active treatment; StableRT, stable disease after partial or complete resection receiving radiotherapy; StableTMZadj, stable disease after partial or complete resection receiving adjuvant temozolomide treatment; StableTMZcRT, stable disease after partial or complete resection receiving concomitant radiotherapy and temozolomide; StaCR2Pro, probability of progression in patients with complete resection; StaPR2Pro, probability of progression in patients with partial resection; Surg2CRGliolan, probability of complete resection with 5-aminolevulinic acid surgery.
FIGURE 3
FIGURE 3
Scatter diagram of Monte Carlo simulation results in the cost-effectiveness plane, National Health Service perspective. A, incremental cost per quality-adjusted life-year (QALY) gained. B, incremental cost per life-year (LY) gained. C, incremental cost per progression-free life-year (PFLY) gained. The gray line represents a willingness-to-pay threshold of €20000 per additional QALY, LY, or PFLY. Results are located in the upper-right quadrant, reflecting a beneficial effect of 5-aminolevulinic acid fluorescence-guided surgery in all health effects evaluated but at a higher cost. In the 3 scatterplots, the majority of the simulation results are located below the threshold line, indicating a very high probability of incremental cost-effectiveness ratio being inferior to €20000 for all health effects evaluated.
FIGURE 4
FIGURE 4
Cost-effectiveness acceptability curves, National Health Service perspective. A, incremental cost-per quality adjusted life-year gained. B, incremental cost per life-year gained. C, incremental cost per progression-free life-year gained. The acceptability curves represent, for several willingness-to-pay threshold values ranging from €0 to €50000, the probability that the incremental cost-effectiveness ratio is below the considered threshold value. 5-ALA, 5-aminolevulinic acid.

References

    1. Merrell RT, Wen PY. Management of Gliomas 2010. Available at: . Accessed September 18, 2011.
    1. Crocetti E, Trama A, Stiller C, et al. Epidemiology of glial and non-glial brain tumors in Europe. Eur J Cancer. 2012;48(10):1532-1542.
    1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16(suppl 4):iv1-iv63.
    1. Curran WJ, Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85(9):704-710.
    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
    1. Stupp R, Tonn JC, Brada M, Pentheroudakis G; ESMO Guidelines Working Group. High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v190-v193.
    1. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3-8.
    1. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62(3):564-576.
    1. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190-198.
    1. Kreth FW, Thon N, Simon M, et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol. 2013;24(12):3117-3123.
    1. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994;34(1):45-60.
    1. Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival: clinical article. J Neurosurg. 2011;114(3):587-594.
    1. Stummer W, Meinel T, Ewelt C, et al. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol. 2012;108(1):89-97.
    1. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401.
    1. Slof J, Díez Valle R, Galván J. Cost-effectiveness of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery. Neurologia. 2014;pii:S0213-4853(13)00286-7. doi: . Available at: . Epub 2014 Jan 24. Accessed April 2014.
    1. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii-iv, ix-221.
    1. Rogers G, Garside R, Mealing S, et al. Carmustine implants for the treatment of newly diagnosed high-grade gliomas. Pharmacoeconomics. 2008;26(1):33-44.
    1. Silva EA, Gouveia Pinto C, Sampaio C, et al. Orientações Metodológicas para Estudos de Avaliação Económica de Medicamentos. INFARMED; 1998. Portugal. Available at: . Accessed October 29, 2012.
    1. Ministério da Saúde (2009b), Diário da República, N°147/2009, 1° suplemento série I de 2009-07-31 - Portaria N° 839-A/2009, de 31 de Julho de 2009. Available at: . Accessed October 29, 2012.
    1. Ministério da Saúde (2009a), Diário da República, N°21/2009, série I de 2009-01-30 - Portaria N° 132/2009, de 30 de Janeiro de 2009. Available at: . Accessed October 29, 2012.
    1. ACSS. Portuguese drug formulary for NHS hospitals. Available at: . Accessed October 29, 2012.
    1. INFARMED. Portuguese National Authority of Medicines and Health Products drug formulary. Available at: . Accessed October 29, 2012.
    1. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011;12(11):997-1003.
    1. NICE. Guide to the Methods of Technology Appraisal. 2004. (Ref N0515) paragraphs 6.2.6.10—11 National Institute for Clinical Excellence; London: 2004. ISBN 1-84257-595-3.
    1. Schucht P, Beck J, Abu-Isa J, et al. Gross total resection rates in contemporary glioblastoma surgery: results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping. Neurosurgery. 2012;71(5):927-935.
    1. Díez Valle R, Tejada Solis S, Idoate Gastearena MA, García de Eulate R, Domínguez Echávarri P, AristuMendiroz J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neurooncol. 2011;102(1):105-113.
    1. Della Puppa A, De Pellegrin S, d’Avella E, et al. 5-Aminolevulinic acid (5-ALA) fluorescence guided surgery of high-grade gliomas in eloquent areas assisted by functional mapping: our experience and review of the literature. Acta Neurochir (Wien). 2013;155(6):965-972.
    1. Laws ER, Parney IF, Huang W, et al. ; Glioma Outcomes Investigators. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99(3):467-473.
    1. Díez Valle R, Slof J, Galván J, Arza C, Romariz C, Vidal C. Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (the VISIONA study) Neurologia. 2014;29(3):131-138.
    1. Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg. 2012;117(6):1032-1038.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren